Electroacupuncture May Aid Depression-Related Insomnia
Quality of sleep significantly improved compared with standard care alone or sham acupuncture
Quality of sleep significantly improved compared with standard care alone or sham acupuncture
Daridorexant is a dual orexin receptor antagonist designed to suppress wake drive by blocking the binding of wake-promoting neuropeptides orexin A and orexin B to its receptors.
Nighttime hot flashes, insomnia severity both down at four weeks versus placebo
50-mg dose shows significant improvement versus placebo for sleep onset, sleep maintenance, and total sleep time
Review the January 2022 notable drug approvals.
This week news of a new treatment for insomnia; The FDA comment on magnesium hypertension claims; Transmucosal buprenorphine linked to dental decay; Researchers assess changes in menstrual cycles in relation to COVID vaccines; And experts have their say on the best diets for 2022.
The FDA has accepted for review the NDA for daridorexant, an investigational dual orexin receptor, for the treatment of insomnia in adults.
The approval was based on data from a 9-week, double-blind, placebo-controlled, crossover study which assessed the effects of Hetlioz in patients with SMS.
While valerian is considered a popular herbal supplement for managing sleep disorders, study outcomes related to its effectiveness have been inconsistent.